Opinion|Videos|April 28, 2026

Emerging Treatment Options for HER2-Positive NSCLC

Author(s)Joshua K. Sabari, MD

New FDA-approved zongepanib boosts responses in HER2-mutant lung cancer, delivering durable control with fewer side effects than standard chemo.

Episodes in this series

EP. 1 Background of Targeting HER2 in NSCLC

EP. 1 Background of Targeting HER2 in NSCLC

EP. 2 Emerging Treatment Options for HER2-Positive NSCLC

EP. 2 Emerging Treatment Options for HER2-Positive NSCLC

EP. 3 Beamion LUNG‑1 Trial: Zongertinib in HER2-Positive NSCLC

EP. 3 Beamion LUNG‑1 Trial: Zongertinib in HER2-Positive NSCLC

EP. 4 Depth and Durability of Response to Zongertinib in HER2-Positive NSCLC

EP. 4 Depth and Durability of Response to Zongertinib in HER2-Positive NSCLC

EP. 5 Safety and Tolerability of Zongertinib in HER2-Positive NSCLC

EP. 5 Safety and Tolerability of Zongertinib in HER2-Positive NSCLC

EP. 6 Next-Generation Sequencing and HER2-Mutations in Metastatic NSCLC

EP. 6 Next-Generation Sequencing and HER2-Mutations in Metastatic NSCLC

Joshua K. Sabari, MD, discusses the standard approaches that have been used historically for treating patients with HER2‑mutant non–small cell lung cancer (NSCLC). These treatments have included chemotherapy alone as well as combination chemotherapy and immunotherapy. According to Sabari, emerging HER2-targeted agents, such as zongertinib, are showing improved efficacy and tolerability vs standard care.

Newsletter

Related Content

1 expert in this video

Second-Line Sequencing After Progression on Zongertinib: ADC, TKI Switch, or Chemotherapy

ByEvan Wu, MD, PhD

May 15th 2026

1 expert in this video

Zongertinib in the Context of Hepatic Impairment, Polypharmacy, and Hepatitis B Reactivation Risk

ByEvan Wu, MD, PhD

May 15th 2026

1 expert is featured in this series.

Safety Profiles and Proactive Adverse Event Management

ByMatthew Gumbleton, MD

May 14th 2026

1 expert is featured in this series.

Financial Access, Patient Assistance Programs, and Adherence Monitoring Strategies

ByDeborah Doroshow, MD, PhD

May 14th 2026

1 expert is featured in this series.

CNS Protection and Risk of Brain Metastases

ByMatthew Gumbleton, MD

May 14th 2026

Latest CME

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Seth A. Wander, MD, PhD; Girish Kunapareddy, MD

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Iowa

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Iowa

Virginia Kaklamani, MD, DSc; Jack W. Erter III, MD, MMHC

Arkansas Association of Cancer Professionals

Arkansas Association of Cancer Professionals

2 Sessions are Available!

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | South Carolina Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | South Carolina Oncology Society

Seth A. Wander, MD, PhD; Kit Lu, MD

Immune Therapies in Practice in 2026: Cellular Therapies, ADCs, Bispecifics, and Beyond

In-Person Event

Immune Therapies in Practice in 2026: Cellular Therapies, ADCs, Bispecifics, and Beyond

May 22, 2026

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Minnesota

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Minnesota

Neil M. Iyengar, MD; Kimberly Ku, MD

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Texas

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Texas

Sheila Donnelly, MD; Virginia Kaklamani, MD, DSc

Updates from Berlin: Oral SERDs in HR+/HER2- Metastatic Breast Cancer – What the Latest Data Really Tell Us

Updates from Berlin: Oral SERDs in HR+/HER2- Metastatic Breast Cancer – What the Latest Data Really Tell Us

May 27, 2026

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Reshma Jagsi, MD, DPhil; Kevin Kalinsky, MD, MS; Hope S. Rugo, MD, FASCO; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

Go to PER in Chicago

In-Person + Virtual Event

Go to PER in Chicago

May 29-31, 2026

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Tennessee Oncology Practice Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Tennessee Oncology Practice Society

Seth A. Wander, MD, PhD; Kamel Abou Hussein, MD

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Washington

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Washington

Alison K. Conlin, MD; Neil M. Iyengar, MD

Updates from Chicago: Oral SERDs in HR+/HER2- Metastatic Breast Cancer – What the Latest Data Really Tell Us

Updates from Chicago: Oral SERDs in HR+/HER2- Metastatic Breast Cancer – What the Latest Data Really Tell Us

June 8, 2026

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Wyoming & Montana

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Wyoming & Montana

Yan Ji, MD; Neil M. Iyengar, MD

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – North Carolina

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – North Carolina

Girish Kunapareddy, MD; Sara M. Tolaney, MD, MPH

Iowa Oncology Society

Iowa Oncology Society

1 Session is Available!

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Nevada Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Nevada Oncology Society

Seth A. Wander, MD, PhD; Ruta D. Rao, MD

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Marla D. Lipsyc-Sharf, MD; Richard Zelkowitz, MD

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology Society

Seth A. Wander, MD, PhD; Kate Baxstrom, MD

Kansas Society of Clinical Oncology

Kansas Society of Clinical Oncology

1 Session is Available!

Louisiana Oncology Society

Louisiana Oncology Society

1 Session is Available!

Missouri Oncology Society

Missouri Oncology Society

1 Session is Available!

New Mexico Society of Clinical Oncology

New Mexico Society of Clinical Oncology

1 Session is Available!

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, FASCO; Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; Paolo Tarantino, MD

25th Annual International Congress on the Future of Breast Cancer® East

In-Person + Virtual Event

25th Annual International Congress on the Future of Breast Cancer® East

July 10-11, 2026

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Establishing the Rationale for ADC and ICI Combinations in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Breaking Down the Rationale for Targeting TROP2 in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

24th Annual International Congress on the Future of Breast Cancer® East

24th Annual International Congress on the Future of Breast Cancer® East

Joyce O’Shaughnessy, MD

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO